SCHEMBL3479693

SCHEMBL3479693

CCS(=O)(=O)N1CCN(c2ccc3c(c2)CN(C)CCN3c2ccccc2)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD3 P35462 7/20 0.48
HTR6 P50406 4/20 0.48
SLC6A2 P23975 2/20 0.45
SLC6A4 P31645 2/20 0.45
SLC6A3 Q01959 2/20 0.45
HRH3 Q9Y5N1 2/20 0.44
DRD2 P14416 3/20 0.43
HTR1A P08908 1/20 0.42
HTR2A P28223 1/20 0.42
HTR2C P28335 1/20 0.42
HTR7 P34969 1/20 0.42
HSD17B10 Q99714 1/20 0.42
MAPT P10636 3/20 0.42
ALDH1A1 P00352 2/20 0.42
NPSR1 Q6W5P4 2/20 0.42
KMT2A Q03164 1/20 0.41
RORC P51449 1/20 0.41
TMEM97 Q5BJF2 2/20 0.41
SIGMAR1 Q99720 2/20 0.41
ADRA2C P18825 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3233345 0.90 SLC6A2 (0.53) DRD3HTR6SLC6A2SLC6A4SLC6A3
SCHEMBL3231425 0.90 MMP13 (0.47) DRD3HTR6SLC6A2SLC6A4SLC6A3
SCHEMBL3232084 0.89 HTR3A (0.54) DRD3HTR6SLC6A2SLC6A4SLC6A3
SCHEMBL3479777 0.88 ADRA2C (0.51) DRD3HTR6SLC6A4HRH3DRD2
SCHEMBL3231453 0.87 HSD17B10 (0.56) DRD3HTR6SLC6A2SLC6A4SLC6A3
SCHEMBL3225754 0.87 SLC6A2 (0.43) DRD3HTR6SLC6A2SLC6A4SLC6A3
SCHEMBL3227352 0.86 THRB (0.49) SLC6A2SLC6A4SLC6A3MAPTALDH1A1
SCHEMBL3229545 0.86 SLC6A2 (0.43) DRD3HTR6SLC6A2SLC6A4SLC6A3
SCHEMBL3222197 0.83 ADAMTS4 (0.42) DRD3HTR6SLC6A2SLC6A4SLC6A3
SCHEMBL3217484 0.81 RORC (0.51) DRD3HTR6SLC6A4HRH3HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096546-B2 Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin ALBANY MOLECULAR RESEARCH, INC. (US) 2015-08-04 US disclosed
US-20100137287-A1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ALBANY MOLECULAR RESEARCH, INC. (US) 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137287-A1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ADRA1B, ADRB1, ADRA1D DRD3 12/4885HTR6 73/4885SLC6A2 28/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.